Fisher BT, Zaoutis TE, Xiao R, et al. - In children with invasive candidiasis, reduced failure rate at 14 days but not 30 days was observed in correlation with receiving initial directed therapy with an echinocandin vs triazoles or amphotericin B formulations (triazole/amphotericin B).

• At 43 International Pediatric Fungal Network sites, 541 patients (235 in the echinocandin group and 306 in the triazole/amphotericin B group) were included in this multinational observational cohort study.

• At 14 days, the echinocandin group had a crude failure rate of 9.8% vs 13.1% for triazole/amphotericin B group.

• Between the groups, there was adjusted 14-day risk difference of −7.1% points, which favors echinocandins.